Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;19(5):2182-2196.
doi: 10.1002/alz.12937. Epub 2023 Jan 15.

Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART

Affiliations

Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART

Alexander J Ehrenberg et al. Alzheimers Dement. 2023 May.

Abstract

The neuromodulatory subcortical system (NSS) nuclei are critical hubs for survival, hedonic tone, and homeostasis. Tau-associated NSS degeneration occurs early in Alzheimer's disease (AD) pathogenesis, long before the emergence of pathognomonic memory dysfunction and cortical lesions. Accumulating evidence supports the role of NSS dysfunction and degeneration in the behavioral and neuropsychiatric manifestations featured early in AD. Experimental studies even suggest that AD-associated NSS degeneration drives brain neuroinflammatory status and contributes to disease progression, including the exacerbation of cortical lesions. Given the important pathophysiologic and etiologic roles that involve the NSS in early AD stages, there is an urgent need to expand our understanding of the mechanisms underlying NSS vulnerability and more precisely detail the clinical progression of NSS changes in AD. Here, the NSS Professional Interest Area of the International Society to Advance Alzheimer's Research and Treatment highlights knowledge gaps about NSS within AD and provides recommendations for priorities specific to clinical research, biomarker development, modeling, and intervention. HIGHLIGHTS: Neuromodulatory nuclei degenerate in early Alzheimer's disease pathological stages. Alzheimer's pathophysiology is exacerbated by neuromodulatory nuclei degeneration. Neuromodulatory nuclei degeneration drives neuropsychiatric symptoms in dementia. Biomarkers of neuromodulatory integrity would be value-creating for dementia care. Neuromodulatory nuclei present strategic prospects for disease-modifying therapies.

PubMed Disclaimer

Conflict of interest statement

Disclosures

AJE has received support for travel from the Rainwater Charitable Foundation and Deutsches Zentrum für Neurodegenerative Erkrankungen, has received consulting fees from Epiodyne Inc., holds stock in Eiger Biopharmecuticals, is a Science Editor for “Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association”, and serves on the executive committee for the Neuromodulatory Subcortical Systems PIA of ISTAART. ST is an advisory board member for Roche, Eisai, Biogen, and Grifols and is an independent data monitoring board member for Biogen, is a senior associate editor for “Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association”, and served on the executive committee for the Neuromodulatory Subcortical Systems PIA of ISTAART during the time this manuscript was written. AIL has received consulting fees from Biogen, Karuna, Cognito Theraputics, and Genuv. QW is listed on US Patent applications 63/138.118 & 63/305.621, and holds stock in Terran Biosciences. CB has received consulting fees from Cyclerion Theraputics, serves on the steering committee of the Italian Society of Psychophysiology, and serves as the immediate past chair of the Electrophysiology PIA of ISTAART. LTG has received support from the Rainwater Charitable Foundation, support for travel from the Alzheimer’s Association, and serves on the executive committee for the Neuromodulatory Subcortical Systems PIA of ISTAART. HILJ, MJD, AJW, DW, NF, SEC, CS, MK, and GS served on the executive committee (unpaid) for the Neuromodulatory Subcortical Systems PIA of ISTAART during the time this manuscript was written. KL, MM, MJB, SD, DH, JRW, MLe, JMS, OE, IR, EL, MLu, CS, MVE, EMV, FR, LH, SV, WMF, YY, MM, CL, MB, AS, JRG, WSK, and RH have no conflicts to disclose.

Figures

FIGURE 1
FIGURE 1
The neuromodulatory subcortical system (NSS) professional interest area recommends investment in research on pathways to selective vulnerability in NSS and how dysfunction and degeneration of NSS contribute to pathogenesis and clinical consequences. Myriad disciplines are positioned to generate knowledge within any of these research themes

References

    1. Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 2009;513:532–41. - PubMed
    1. Bargmann CI, Marder E. From the connectome to brain function. Nat Methods 2013;10:483–90. - PubMed
    1. Marder E Neuromodulation of neuronal circuits: back to the future. Neuron 2012;76:1–11. - PMC - PubMed
    1. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237–9. - PubMed
    1. Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 1984;43:359–68. - PubMed

Publication types